These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6735277)

  • 1. Automated spectrophotometric heparin assays. Comparison of methods.
    van Putten J; van de Ruit M; Beunis M; Hemker HC
    Haemostasis; 1984; 14(2):195-204. PubMed ID: 6735277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated determination of heparin with chromogenic substrates.
    van Putten J; van de Ruit M; Beunis M; Hemker HC
    Haemostasis; 1984; 14(2):184-94. PubMed ID: 6735276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of low molecular weight heparin in clinical laboratory.
    van Putten J; van de Ruit M; Beunis M; Hemker HC
    Haemostasis; 1984; 14(2):205-10. PubMed ID: 6203817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of platelet factor 4 (PF4) on assays of plasma heparin.
    Levine SP; Sorenson RR; Harris MA; Knieriem LK
    Br J Haematol; 1984 Aug; 57(4):585-96. PubMed ID: 6743573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of heparin therapy with the activated partial thromboplastin time and chromogenic substrate assays.
    Fey MF; Lang M; Furlan M; Beck EA
    Thromb Haemost; 1987 Oct; 58(3):853-5. PubMed ID: 3481140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin III activity (residual thrombin activity) in plasma from non-medicated or heparinized horses.
    Darien BJ; Potempa J; Moore JN; Travis J
    Vet Res Commun; 1989; 13(1):31-46. PubMed ID: 2773304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin.
    Bates SM; Weitz JI; Johnston M; Hirsh J; Ginsberg JS
    Arch Intern Med; 2001 Feb; 161(3):385-91. PubMed ID: 11176764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
    Kitchen S; Theaker J; Preston FE
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
    Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity.
    ten Cate H; Lamping RJ; Henny CP; Prins A; ten Cate JW
    Clin Chem; 1984 Jun; 30(6):860-4. PubMed ID: 6723041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-step chromogenic equivalent of activated partial thromboplastin time evaluated for clinical application.
    Ponjee GA; Vader HL; de Wild PJ; Janssen GW; van der Graaf F
    Clin Chem; 1991 Jul; 37(7):1235-44. PubMed ID: 1855296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
    Baker BA; Adelman MD; Smith PA; Osborn JC
    Arch Intern Med; 1997 Nov; 157(21):2475-9. PubMed ID: 9385299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay.
    Kostousov V; Nguyen K; Hundalani SG; Teruya J
    Arch Pathol Lab Med; 2014 Nov; 138(11):1503-6. PubMed ID: 25357112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.